TSPO and glioblastoma: Notably, regions with pronounced TSPO-PET signal elevation in the contralateral hemisphere of patients with glioblastoma compared to controls (Fig. 1E) showed stronger impact on overall survival (Fig. 3G, i.e., mesial temporal median OS: 9.1 vs. 19.1 months, Log-rank test: Χ2 = 9.42, P = 0.002) and outperformed regions with lower TSPO elevation (Fig. 3H, i.e., basal ganglia median OS: 10.5 vs. 12.4, Log-rank test: Χ2 = 0.38, P = 0.537).